The negative P/E ratio and lack of a forward earnings multiple underscore the market's skepticism regarding the company's ability to achieve sustainable margins. This valuation level appears to price in significant execution risk, implying that the current market capitalization is largely supported by the remaining cash balance rather than future growth prospects.

The inability to maintain positive operating margins suggests that the current business model may be fundamentally misaligned with its cost structure. Investors should monitor whether the shift toward higher-margin therapeutic products can eventually offset the logistical burdens inherent in the legacy concentrate business, though current trends suggest this remains a distant prospect.

The fluctuation in the cash conversion cycle suggests that management is struggling to optimize working capital, likely due to the high customer concentration among mid-sized dialysis chains. This lack of efficiency warrants further investigation into whether the company's logistics-based moat is actually creating a drag on cash flow rather than a competitive advantage.

While the company has avoided excessive leverage, the reliance on equity-based funding or cash reserves to bridge operational gaps appears increasingly likely. The absence of a robust interest coverage ratio suggests that any future capital requirements may come at a high cost or result in significant dilution for existing shareholders.